🧠This Week in Immunology: Light Therapy for Crohn’s, Skin Disease Declared a Priority, and a $9.5B Biotech Acquisition
Stay up to date with the latest developments in immunology—spanning first-in-human trials, public health milestones, and multi-billion dollar immunology expansions:
💡 PhotoPill launches a clinical trial for its IBD-Cap capsule in Crohn’s disease—offering non-invasive, drug-free light therapy for flare-up management.
🌍 The World Health Organization officially declares skin disease a global public health priority—impacting over 2 billion people and calling for urgent action.
💊 Bambusa doses the first patient in its Phase 1 trial for BBT002 and expands U.S. IND clearance for BBT001—targeting multi-organ inflammatory pathways.
✅ NICE recommends mirikizumab for Crohn’s patients unresponsive to biologics—45% achieved remission at one year in Phase 3 trials.
🔬 Enthera publishes data for Ebrasodebart—demonstrating mucosal healing by targeting TMEM219 in ulcerative colitis models.
🧴 LEO Pharma begins a Phase 2a trial for delgocitinib cream in chronic PPP—building on approvals for hand eczema treatment.
💸 Kamari Pharma raises $23M to develop its TRPV3 inhibitor KM023—now entering Phase 1b for rare genetic skin diseases like Olmsted syndrome.
🧬 Recludix and Sanofi progress oral STAT6 inhibitor REX-8756—triggering a $50M milestone, with an IND filing expected in late 2025.
🤝 Sanofi to acquire Blueprint Medicines in a $9.5B deal—adding Ayvakit and two pipeline immunology assets to its growing portfolio.
📢 Stay Ahead in Immunology Research! ✅ Like, share, and subscribe for weekly updates on the latest in immunology and autoimmune innovation ✅ Visit www.lqventures.com for expert healthcare insights and consulting services ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on immunology innovations and clinical research 🔔 Turn on notifications so you never miss an update!
The scoops deal with published (classical or OPEN) and grey literature (blogs, websites, social networks, press releases) allowing rapid access to recently published relevant information
Â
May 29, 2015 you were 26796 visitors, viewing this topic 34.5K times., 4900 scoops
June 2020 : >7.3K scoops, >94.5K visitors, #121K views
December 2023: >8K scoops, >97,7K vis, >171,3K views
May 2025: >8.2K scoops, >98.2 visitors, >177,8 views
Gilbert C FAURE's insight:
This topic is focusing mainly on fundamental systemic immunology.
Some subjects are particularly adressed, according to my personal interests in research or teaching, for instance
🧠This Week in Immunology: Light Therapy for Crohn’s, Skin Disease Declared a Priority, and a $9.5B Biotech Acquisition
Stay up to date with the latest developments in immunology—spanning first-in-human trials, public health milestones, and multi-billion dollar immunology expansions:
💡 PhotoPill launches a clinical trial for its IBD-Cap capsule in Crohn’s disease—offering non-invasive, drug-free light therapy for flare-up management.
🌍 The World Health Organization officially declares skin disease a global public health priority—impacting over 2 billion people and calling for urgent action.
💊 Bambusa doses the first patient in its Phase 1 trial for BBT002 and expands U.S. IND clearance for BBT001—targeting multi-organ inflammatory pathways.
✅ NICE recommends mirikizumab for Crohn’s patients unresponsive to biologics—45% achieved remission at one year in Phase 3 trials.
🔬 Enthera publishes data for Ebrasodebart—demonstrating mucosal healing by targeting TMEM219 in ulcerative colitis models.
🧴 LEO Pharma begins a Phase 2a trial for delgocitinib cream in chronic PPP—building on approvals for hand eczema treatment.
💸 Kamari Pharma raises $23M to develop its TRPV3 inhibitor KM023—now entering Phase 1b for rare genetic skin diseases like Olmsted syndrome.
🧬 Recludix and Sanofi progress oral STAT6 inhibitor REX-8756—triggering a $50M milestone, with an IND filing expected in late 2025.
🤝 Sanofi to acquire Blueprint Medicines in a $9.5B deal—adding Ayvakit and two pipeline immunology assets to its growing portfolio.
📢 Stay Ahead in Immunology Research! ✅ Like, share, and subscribe for weekly updates on the latest in immunology and autoimmune innovation ✅ Visit www.lqventures.com for expert healthcare insights and consulting services ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on immunology innovations and clinical research 🔔 Turn on notifications so you never miss an update!
Sixty years after its discovery as the first human tumour virus, Epstein–Barr virus (EBV)-specific therapies and vaccines have entered clinical trials. These might not only be applicable for EBV-associated malignancies, where the virus was originally discovered, but also to immunopathologies, including the autoimmune disease multiple sclerosis, which might be triggered in susceptible individuals by primary EBV infection. This Review discusses the surprisingly large spectrum of diseases that EBV seems to cause, as well as which of these might be treated by the therapeutic approaches that are currently being developed or are already clinically applied. New pharmacological inhibitors, antibody therapies, adoptive T cell therapies and active vaccinations are beginning to offer possibilities to target the various EBV infection programmes that are associated with different diseases. These novel developments might allow us to specifically target EBV rather than its host cells in virus-associated pathologies. Sixty years after the discovery of the Epstein–Barr virus (EBV), Münz discusses new developments in the immunobiology of the first discovered human tumour virus, including vaccines and the role of EBV in the initiation of autoimmune diseases, especially multiple sclerosis.
Thymic cortex and medulla epithelia displayed distinctive interferon-responsive signatures defined by lineage-specific chromatin accessibility. We explored the effects of type I and II interferons on thymic epithelial progenitor differentiation from induced pluripotent stem cells. Type II interferon was essential for expressing proteasome and antigen-presenting molecules, whereas type I or II interferons were essential for inducing different cytokines in thymic epithelial progenitor cells. Our findings suggest that interferons are critical to cortical and medullary thymic epithelial cell differentiation.
B-cell receptor (BCR) complexes are expressed on the surface of a B-cell and are critical in antigen recognition and modulating the adaptive immune response. Even though the relevance of antibodies has been known for almost a hundred years, the antigen-dependent activation mechanism of B-cells has remained elusive. Several models have been proposed for BCR activation, including cross-linking, conformation-induced oligomerization, and dissociation activation models. Recently, the first cryo-EM structures of the human B-cell antigen receptor of the IgM and IgG isotypes have been published that validates the asymmetric organization of the BCR complex. Here, we carry out extensive molecular dynamics simulations to probe the conformational changes upon antigen binding and the influence of the membrane lipids. We identify two critical dynamical events that could be associated with antigen-dependent activation of BCR. First, antigen binding causes increased flexibility in regions distal to the antigen binding site. Second, antigen binding alters the rearrangement of IgM transmembrane helices, including the relative interaction of Igα/Igβ that mediates intracellular signaling. Furthermore, these transmembrane rearrangements lead to changes in localized lipid composition. Our work indirectly supports the conformational-change induced models of BCR activation and contributes to the understanding of the antigen-dependent activation mechanism of BCRs. Extensive multiscale modeling of B-cell receptor in the presence and absence of a model antigen in a complex membrane environment revealed the dynamical events throughout the receptor and surrounding membrane upon antigen binding to the receptor.
Gilbert C FAURE's insight:
Antibodies despite being a cornerstone of modern medicine and driving a multibillion-dollar industry, we still don’t fully understand the fundamental mechanisms behind the production of these fascinating molecules. A recent study published in Communications Biology combines Cryo-EM experiments and Molecular Dynamics simulations to propose a new, comprehensive theory of BCR (pre-antibody) dynamics. The study suggests that the interaction between pre-IgM and Ig alpha/beta is asymmetric, challenging previous assumptions. Additionally, it highlights the role of oligomerization surfaces that appear and disappear in BCRs—if confirmed, this could have significant implications for the development of therapeutic antibodies and our understanding of immune health and disease. This exciting work needs further experimental validation, particularly in autoimmune diseases. After more than 120 years of immunology research, this field continues to surprise us!
University of Melbourne’s Professor Laura Mackay, has been presented with the National Health and Medical Research Council Elizabeth Blackburn Investigator Grant Award for being the highest-ranking female applicant to receive an NHMRC Investigator Grant.
Please check out our paper published in Nature that identifies CREM as a key checkpoint limiting CAR NK cell function. We show that CRISPR knockout of CREM significantly enhanced anti-tumor activity, implicating a broader role in NK & T cell regulation. Huge congrats to Hind Rafei and our incredible collaborators whose hard work made this possible. Excited to explore the translation of this approach to the clinic.
Here we identify the transcription factor cyclic AMP response element modulator (CREM) as a crucial regulator of NK cell function
Â
Although previous research has highlighted the inhibitory effects of CREM in T cells and macrophages15,19,20, its specific role in NK cells, especially in the context of CAR-NK cell antitumour activity, remains underexplored.
Â
Subramanyam, S. H. & Tenbrock, K. The cAMP responsive element modulator (CREM) is a regulator of CD4+ T cell function. Biol. Chem. 402, 1591–1596 (2021).
✅ It’s open access—free to read and share! Let’s spread the science! 🚀
Natural killer (NK) play a key role in controlling tumor dissemination by mediating cytotoxicity towards cancer cells without the need of education. These cells are pivotal in eliminating circulating tumor cells (CTCs) from the bloodstream, thus limiting cancer spread and metastasis. However, aggressive CTCs can evade NK cell surveillance, facilitating tumor growth at distant sites. In this review, we first discuss the biology of NK cells, focusing on their functions within the tumor microenvironment (TME), the lymphatic system, and circulation. We then examine the immune evasion mechanisms employed by cancer cells to inhibit NK cell activity, including the upregulation of inhibitory receptors. Finally, we explore the clinical implications of monitoring circulating biomarkers, such as NK cells and CTCs, for therapeutic decision-making and emphasize the need to enhance NK cell-based therapies by overcoming immune escape mechanisms.
Background Autophagy is a lysosome-dependent degradation pathway for recycling intracellular materials and removing damaged organelles, and it is usually considered a prosurvival process in response to stress stimuli.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Your new post is loading...
